Keytruda/Lenvima CRL To Give Roche More Space In 1L HCC?
But Phase III Is Already Enrolled
Executive Summary
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
You may also be interested in...
AstraZeneca's Imfinzi/Tremelimumab Combo Conquers HIMALAYA
After the combination's success in the non-small cell lung cancer POSEIDON study, AstraZeneca's Imfinzi and tremelimumab could now be on the way to approval as a first-line treatment for hepatocellular carcinoma.
Earlier Use of Exelixis/Ipsen's Cabozantinib Hits Hurdle In Liver Cancer
Exelixis/Ipsen’s novel combination of cabozantinib and atezolizumab has produced mixed top-line results from the Phase III COSMIC-312 study, and although the companies are pressing ahead with further analyses, the doublet may struggle to compete in the first-line advanced liver cancer setting.
Merck & Co.’s Keytruda Stakes Another Adjuvant Flag, In RCC
Adjuvant renal cell carcinoma is a potentially lucrative indication for any checkpoint inhibitor; Merck & Co. flagship Keytruda is the first to demonstrate benefit in a Phase III study, although rivals are in pursuit.